May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Brain-Derived Neurotrophic Factor (BDNF) Released From Engineered Mesenchymal Stem Cells (MSCs) Attenuates Glutamate- and Hydrogen Peroxide-Mediated Death of Staurosporine Differentiated RGC-5 Cells
Author Affiliations & Notes
  • D. S. Sakaguchi
    Iowa State University, Ames, Iowa
    Genetics, Devel & Cell Biol and Neurosci Prog,
  • M. M. Harper
    Iowa State University, Ames, Iowa
    Genetics, Devel & Cell Biol and Neurosci Prog and Vet. Clinical Sci.,
  • L. Adamson
    Iowa State University, Ames, Iowa
    Genetics, Devel & Cell Biol and Neurosci Prog,
  • B. Blits
    Netherlands Institute for Neuroscience, Amsterdam, The Netherlands
  • M. B. Bunge
    Miami Project to Cure Paralysis, Miami, Florida
  • S. D. Grozdanic
    Iowa State University, Ames, Iowa
    Veterinary Clinical Sciences,
  • Footnotes
    Commercial Relationships  D.S. Sakaguchi, None; M.M. Harper, None; L. Adamson, None; B. Blits, None; M.B. Bunge, None; S.D. Grozdanic, None.
  • Footnotes
    Support  NIGMS RO1-GM072005-01, The Glaucoma Foundation NY, VA-RRD Grant C3919R
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 2074. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      D. S. Sakaguchi, M. M. Harper, L. Adamson, B. Blits, M. B. Bunge, S. D. Grozdanic; Brain-Derived Neurotrophic Factor (BDNF) Released From Engineered Mesenchymal Stem Cells (MSCs) Attenuates Glutamate- and Hydrogen Peroxide-Mediated Death of Staurosporine Differentiated RGC-5 Cells. Invest. Ophthalmol. Vis. Sci. 2008;49(13):2074. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : The purpose of this study was to determine the efficacy of cell-based delivery of BDNF from genetically modified MSCs for neuroprotection of RGC-5 cells.

Methods: : RGC-5 cells were differentiated with staurosporine (SS) and exposed to the cellular stressors glutamate and H2O2, and remaining cells quantified as a percentage of control. BDNF was provided to glutamate or H2O2 treated RGC-5s to examine its neuroprotective capacity via co-culture across a porous membrane insert using MSCs engineered with a lentiviral vector (BDNF-MSCs). As a positive control, recombinant human BDNF (rhBDNF) was added to RGC-5 cells treated with cellular stressors.

Results: : After SS differentiation RGC-5s developed complex morphologies, and a significant increase in the proportion of RGC-5s immunoreactive for TUJ 1 and Brn3a was observed. Differentiated RGC-5s also had prominent TrkB staining, demonstrating they had the high-affinity BDNF receptor. Treatment of SS differentiated RGC-5s with glutamate and H2O2, produced significant cell death (56.0 ± 7.02 and 48.90 ± 4.58% of control cells, respectively) as compared to carrier-solution treated cells. We confirmed that cell death was occurring by using Sytox to label dying cells. Our results demonstrate that BDNF-MSCs were able to preserve more RGC-5 cells after treatment with glutamate (80.0 ± 5.40% cells remaining) than control GFP expressing MSCs (GFP-MSCs, 57.29 ± 1.89%, p < 0.01). BDNF-MSCs also preserved more RGC-5s after treatment with H2O2 (65.6 ± 3.47%) than GFP-MSCs (46.0 ± 4.20%, p < 0.01). These results were confirmed by using purified rhBDNF.

Conclusions: : Staurosporine differentiated RGC-5s have phenotypic and morphological properties consistent with retinal neurons, and they respond to the cellular stressors glutamate and H2O2 in similar fashion. Additionally, we have demonstrated BDNF can attenuate RGC-5 cell death due to these stressors. Our results demonstrate that genetically-modified MSCs are effective vehicles to deliver BDNF to compromised neural-like cells in an in vitro disease model, suggesting this may be a useful in vivo treatment for chronic retinal diseases.

Keywords: neuroprotection • ganglion cells • growth factors/growth factor receptors 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×